NCT03886311View on ClinicalTrials.gov

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

December 31, 2030

Study Completion Date

July 31, 2031

Conditions
Sarcoma
Interventions
DRUG

Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]

Talimogene laherparepvec, 1Bil is given intratumorally every 2 weeks according to tumor size

DRUG

Nivolumab IV Soln 100 MG/10ML

NIVOLUMAB 240 mg IV over 30 min q 2 weeks

DRUG

Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution

TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks

Trial Locations (1)

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

All Listed Sponsors
lead

Sarcoma Oncology Research Center, LLC

OTHER